# CORRESP — Ovid Therapeutics Inc.  (OVID)  (CIK 0001636651)

> <strong>Ovid Therapeutics Inc.  (OVID)  (CIK 0001636651) → SEC staff</strong> · filed 2025-12-19 · ticker OVID · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001193125-25-327040
- **Form:** CORRESP
- **Filer:** Ovid Therapeutics Inc.  (OVID)  (CIK 0001636651)
- **CIK:** 0001636651
- **Ticker:** OVID
- **Filed:** 2025-12-19
- **SIC industry:** 2834
- **HQ:** New York, NY

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1636651/000119312525327040/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1636651&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for Ovid Therapeutics Inc.  (OVID)  (CIK 0001636651)

- CORRESP — 2026-04-23 — /comment-letter/0001193125-26-174064
- UPLOAD — 2026-04-23 — /comment-letter/0000000000-26-004178

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Ovid Therapeutics Inc.  (OVID)  (CIK 0001636651) (CIK 0001636651), filed 2025-12-19, accession 0001193125-25-327040. Retrieved via MORVS 2026-11-19 from https://api.morvs.ai/comment-letter/0001193125-25-327040.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*
